Independent committee recommends the FDA approve Eli Lilly’s Alzheimer’s drug donanemab

​ On Monday, a panel of independent advisers to the US Food and Drug Administration voted to endorse Eli Lilly’s drug donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease, agreeing that it was safe and effective. Read More Breaking News, Latest News and Videos | CNN